US20060051417A1 - Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof - Google Patents

Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof Download PDF

Info

Publication number
US20060051417A1
US20060051417A1 US11/202,715 US20271505A US2006051417A1 US 20060051417 A1 US20060051417 A1 US 20060051417A1 US 20271505 A US20271505 A US 20271505A US 2006051417 A1 US2006051417 A1 US 2006051417A1
Authority
US
United States
Prior art keywords
extended release
pramipexole
tablet formulation
release tablet
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/202,715
Other languages
English (en)
Inventor
Thomas Friedl
Wolfram Eisenreich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34926161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20060051417(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Assigned to BOEHRINGER INGELHEIM INTERNATIONAL GMBH reassignment BOEHRINGER INGELHEIM INTERNATIONAL GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: EISENREICH, WOLFRAM, FRIEDL, THOMAS
Publication of US20060051417A1 publication Critical patent/US20060051417A1/en
Priority to US12/410,855 priority Critical patent/US20090182024A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention is directed to an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same, and use thereof.
  • Pramipexole is a known dopamine D2 receptor agonist. It is structurally different from the ergot-derived drugs, e.g., bromocriptine or pergolide. It is also pharmacologically unique in that it is a full agonist and has receptor selectivity for the dopamine D2 family of dopamine receptors.
  • Pramipexole is designated chemically as (S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole and has the molecular formula C 10 H 17 N 3 S and a relative molecular mass of 211.33.
  • the chemical formula is as follows:
  • Pramipexole dihydrochloride monohydrate (molecular formula C 10 H 21 Cl 2 N 3 OS; relative molecular mass 302.27).
  • Pramipexole dihydrochloride monohydrate is a white to off-white, tasteless, crystalline powder. Melting occurs in the range of 296° C. to 301° C., with decomposition.
  • Pramipexole is a chiral compound with one chiral center. Pure (S)-enantiomer is obtained from the synthetic process by chiral recrystallization of one of the intermediates during synthesis.
  • Pramipexole dihydrochloride monohydrate is a highly soluble compound. Water solubility is more than 20 mg/mL and solubility in buffer media is generally above 10 mg/mL between pH 2 and pH 7.4. Pramipexole dihydrochloride monohydrate is not hygroscopic, and has a highly crystalline nature. Under milling, the crystal modification (monohydrate) does not change. Pramipexole is very stable in the solid state, yet in solution it is light sensitive.
  • Pramipexole immediate release (IR) tablets were first authorized in the USA in 1997, followed over the course of the next years by marketing authorizations in the European Union (EU), Switzerland, Canada, and South America as well as in countries in Eastern Europe, the Near East, and Asia.
  • EU European Union
  • EU European Union
  • South America as well as in countries in Eastern Europe, the Near East, and Asia.
  • Pramipexole IR tablets are indicated in the EU and US for the treatment of signs and symptoms of either early Parkinson's Disease or advanced Parkinson's Disease in combination with levodopa.
  • the IR tablets have to be taken 3 times a day.
  • pramipexole IR tablets are rapidly and completely absorbed following oral administration.
  • the absolute bioavailability is greater than 90% and the maximum plasma concentration occurs within 1 to 3 hours.
  • the rate of absorption is reduced by food intake but not the overall extent of absorption.
  • Pramipexole shows linear kinetics and a relatively small inter-patient variation of plasma levels.
  • the elimination half-life (t 1/2 [h]) varies from 8 hours in the young to 12 hours in the elderly.
  • modified release of active ingredient(s) allows simplification of the patient's administration scheme by reducing the amount of recommended daily intakes, improves patient's compliance, and attenuates adverse events, e.g., related to high plasma peaks.
  • Modified release pharmaceutical preparations regulate the release of the incorporated active ingredient or ingredients over time and comprise formulations with a controlled, a prolonged, a sustained, a delayed, a slow or an extended release, so they accomplish therapeutic or convenience objectives not offered by conventional dosage forms such as solutions or promptly dissolving dosage forms.
  • a modified or extended release of active ingredient(s) from a pharmaceutical preparation may be accomplished by homogeneously embedding the active ingredient(s) in a hydrophilic matrix, being a soluble, partially soluble or insoluble network of viscous, hydrophilic polymers, held together by physical or chemical entanglements, by ionic or crystalline interactions, by complex formation, by hydrogen bonds or van der Waals forces.
  • the hydrophilic matrix swells upon contact with water, thereby creating a protective gel layer from which the active ingredient(s) is (are) slowly, gradually, continuously released in time either by diffusion through the polymeric network, by erosion of the gel layer, by dissolution of the polymer, or by a combination of these release mechanisms.
  • WO 2004/010997 describes a sustained-release pharmaceutical composition in a form of an orally deliverable tablet comprising a water-soluble salt of pramipexole, dispersed in a matrix comprising a hydrophilic polymer and a starch having a tensile strength of at least about 0.15 kN cm ⁇ 2 , preferably at least about 0.175 kN cm ⁇ 2 , and more preferably at least about 0.2 kN cm ⁇ 2 , at a solid fraction representative of the tablet.
  • the disclosure thereof is concentrated to provide a composition with sufficient hardness yield during a high-speed tabletting operation, in particular to resist erosion during application of a coating layer.
  • WO 2004/010999 discloses an orally deliverable pharmaceutical composition
  • a therapeutically effective amount of pramipexole or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient the composition exhibiting at least one of (a) an in vitro release profile wherein on average no more than about 20% of the pramipexole is dissolved within 2 hours after placement of the composition in a standard dissolution test; and (b) an in vivo pramipexole absorption profile following single dose oral administration to healthy adult humans wherein the time to reach a mean of 20% absorption is greater than about 2 hours and/or the time to reach a mean of 40% absorption is greater than about 4 hours.
  • any formulation having an extended or controlled release profile designed for a once daily application would meet the above requirements for which a general teaching how to adjust such a profile is missing.
  • pramipexole or a pharmaceutically acceptable salt thereof may be used in formulations as once daily extended (or slow) release tablets and two alternative formulation principles allow different release rate types dependent or independent from the pH value.
  • One embodiment of the present invention relates to an extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix, the matrix comprising at least two water swelling polymers, wherein one of the polymers is pregelatinized starch, and wherein another one of the polymers is an anionic polymer.
  • the invention relates to an extended release tablet formulation, wherein the anionic polymer is selected from the group of optionally crosslinked acrylic acid polymers, methacrylic acid polymers, alginates and carboxy methyl cellulose.
  • an extended release tablet formulation wherein the anionic polymer is a crosslinked acrylic acid polymer and wherein the content of the optionally crosslinked acrylic acid polymer in the matrix is from about 0.25 wt.-% to about 25 wt.-%, and preferably from about 0.5 wt.-% to about 15 wt.-%, and preferably from about 1 wt.-% to about 10 wt.-%.
  • an extended release tablet formulation further comprising a water swelling polymer which is not pregelatinized starch or an anionic polymer and which is preferably selected from hydroxypropylcellulose or hydroxypropyl methyl cellulose.
  • an extended release tablet formulation wherein the water swelling polymer which is not pregelatinized starch or an anionic polymer is hydroxypropyl methyl cellulose and wherein the content of hydroxypropyl methyl cellulose in the matrix is from about 10 wt.-% to about 75 wt.-%, and preferably from about 25 wt.-% to about 65 wt.-%.
  • an extended release tablet formulation wherein the matrix comprises about:
  • the extended release formulations according to the present invention intended for oral administration allow to select and estimate which in vitro release characteristic and timing of a formulation is most suitable to achieve the desired in vivo plasma profiles preferably with a once daily application. Therefore, two different formulation principles have been developed for a single unit matrix tablet, i.e., two formulation principles having different release rate types are provided and a different pH dependency is available. These alternative formulations are beneficial to patients as the extended release drug delivery will allow patients to treat their symptoms with a single daily dose, thereby increasing patient convenience and compliance.
  • in vitro release characteristic is directed to a release characteristic as obtained in a kind of normally used liquid medium for in vitro experiments wherein the release of active ingredient from the extended release formulation can occur, i.e., for example, in in vitro dissolution media, but also in body fluids or simulated body fluids, more in particular in the gastrointestinal fluids.
  • extended release should be understood in contrast to an immediate release, the active ingredient is gradually, continuously liberated over time, sometimes slower or faster, dependent or independent from the pH value.
  • the term indicates that the formulation does not release the full dose of the active ingredient immediately after oral dosing and that the formulation allows a reduction in dosage frequency, following the definition for extended release, interchangeable with slow release.
  • a slow or extended release, used synonymously with prolonged action, sustained release, or modified release, dosage form is a dosage form that allows at least a reduction in dosing frequency or a significant increase in patient compliance or therapeutic performance as compared to that presented as a conventional dosage form (e.g., as a solution or an immediate drug-releasing, conventional solid dosage form).
  • a release characteristic which is pH-independent indicates that the release characteristic is virtually the same in different pH media.
  • the extended release tablets of the present invention apply a swelling and partly eroding polymer matrix leading to a square root of time to exponential in vitro release characteristic, formulation a) is widely independent from the pH value in the range from pH 1 to 7.5, and formulation b) is (slightly) faster in simulated gastric juice having a pH ⁇ 4.5 but is independent from the pH value in the range from 4.5 to 7.5.
  • a faster release in simulated gastric juice versus slower release in the intestinal fluid can be advantageous in cases where a loading dose effect from the dosage form is desired, whereas a widely pH independent release profile can be advantageous to reduce the risk of dose dumping and food effects.
  • formulation a) is understood the tablet formulation wherein the matrix comprises the composition as above-defined under a) and under “formulation b)” is understood the tablet formulation wherein the matrix comprises the composition as above-defined under b).
  • the water swelling polymer present in both alternate tablet formulations a) and b) of the present invention represents at least pregelatinized starch as one hydrophilic water swelling polymer constituting the extended release matrix which slowly releases the pramipexole or its salt as active ingredient.
  • the polymer swells upon contact with aqueous fluid following administration, resulting in a viscous, drug release regulating gel layer.
  • polymers present in the formulation of the invention in addition to pregelatinized starch are water swelling substantially neutral polymers or water swelling anionic polymers.
  • water swelling substantially neutral polymers comprises alkylcelluloses, such as, methyl cellulose; hydroxyalkylcelluloses, for example, hydroxy methyl cellulose, hydroxyethyl cellulose, hydroxypropylcellulose and hydroxybutyl cellulose; hydroxyalkyl alkylcelluloses, such as hydroxyethyl methyl cellulose and hydroxypropyl methyl cellulose; carboxyalkylcellulose esters; other natural, semi-synthetic, or synthetic di-, oligo-, and polysaccharides such as galactomannans, tragacanth, agar, guar gum, and polyfructans; methacrylate copolymers; polyvinyl alcohol; polyvinylpyrrolidone, copolymers of polyvinylpyrrolidone with vinyl acetate; combinations of polyvinyl alcohol and polyvinylpyrrolidone; polyalkylene oxides such as polyethylene oxide and polypropylene oxide and copolymers
  • HPMC Hydroxypropyl methyl cellulose
  • HPMC type 2208 contains 19-24% by weight methoxy and 4-12% by weight hydroxypropoxy substituents.
  • Hydroxypropyl cellulose having a viscosity higher than 1,500 mPa.s is preferred, in particular hydroxypropyl cellulose having a viscosity in the range from about 1500 to about 3000 mPa.s, preferably from 4000 to 6500 mPa.s (2% aqueous solutions), e.g., the KLUCEL® series such as KLUCEL® M (Hercules, Wilmington, USA).
  • pramipexole or a salt thereof can be released from a hydrophilic matrix: dissolution, erosion and diffusion.
  • Pramipexole or its salt will be released by the dissolution mechanism when it is homogeneously dispersed in a matrix network of a soluble polymer. The network will gradually dissolve in the gastrointestinal tract, thereby gradually releasing its load. The matrix polymer can also gradually be eroded from the matrix surface, likewise releasing pramipexole or its salt in time.
  • pramipexole When pramipexole is processed in a matrix made up of an insoluble polymer, it will be released by diffusion: the gastrointestinal fluids penetrate the insoluble, sponge-like matrix and diffuse back out loaded with drug.
  • the water swelling polymers constituting the matrix mainly provide for the controlled pharmacokinetic release profile of the preparation.
  • the release profile can be tuned, i.e., larger amounts of swelling polymer lead to a more pronounced sustained release effect and vice versa.
  • the amount of water swelling polymer in the present formulation ranges from about 30 to about 99% by weight.
  • the ratio of the polymers also influences the release profile of the preparation.
  • a combination of different polymers offers the possibility of combining different mechanisms by which pramipexole is released from the matrix. Such combination facilitates control of the pharmacokinetic release profile of the preparation at will.
  • the weight percentage of hydroxypropyl methyl cellulose preferably ranges from 25 to about 62%; the weight percentage of hydroxypropyl cellulose preferably ranges between about 0% and about 16%.
  • pramipexole or a salt thereof from a matrix containing hydroxypropyl cellulose and hydroxypropyl methyl cellulose occurs by a combined set of release mechanisms. Due to the higher solubility of hydroxypropyl methyl cellulose compared with hydroxypropyl cellulose, the former will gradually dissolve and erode from the matrix, whereas the latter will more act as a sponge-like matrix former releasing the active ingredient mainly by diffusion.
  • the extended release tablet formulation according to formulation a) is pH-independent. Therefore, the disadvantage that food related dose-dumping may be encountered is avoided.
  • the problem of food related dose-dumping in fed patients can be attributed to a lot of factors such as the mechanical forces that are exerted by the stomach on its content and thus on an ingested preparation as well as the different pH regions of the gastrointestinal tract. Since the pH values encountered in the gastrointestinal tract vary not only with the region of the tract, but also with the intake of food, an extended release formulation preferably also has to provide an extended release profile and in particular has to avoid dose-dumping regardless whether the patient is in fasted or fed conditions.
  • the oral extended release formulation a) may retain its pharmacokinetic release profile along its way through the gastrointestinal tract so as to avoid undesirable fluctuations in drug plasma concentrations or complete dose-dumping, in particular avoids dose-dumping in different regions of the gastrointestinal tract.
  • the formulation of the present invention may also optionally comprise further excipients, i.e., pharmaceutically acceptable formulating agents, in order to promote the manufacture, compressibility, appearance and taste of the preparation.
  • pharmaceutically acceptable formulating agents comprise, for example, diluents or fillers, glidants, binding agents, granulating agents, anti-caking agents, lubricants, flavors, dyes, and preservatives.
  • Other conventional excipients known in the art can also be included.
  • the filler may be selected from soluble fillers, for example, sucrose, lactose, in particular lactose monohydrate, trehalose, maltose, mannitol, sorbitol, inulin, and from insoluble fillers, for example, dicalcium or tricalcium phosphate and talc.
  • soluble fillers for example, sucrose, lactose, in particular lactose monohydrate, trehalose, maltose, mannitol, sorbitol, inulin
  • insoluble fillers for example, dicalcium or tricalcium phosphate and talc.
  • lactose can be used.
  • One type of lactose preferably used in the present invention is lactose monohydrate 200 mesh (DMV, Veghel, The Netherlands).
  • Another lactose monohydrate, lactose monohydrate of the type DCL 11 can also preferably be used.
  • the notation DCL refers to “Direct Compression Lactose”.
  • the number 11 is a reference number of the manufacturer.
  • a water soluble active ingredient like the one described in this invention, more preferably water insoluble fillers, such as starch and starch derivates, microcrystalline cellulose, dibasic calcium phosphate dihydrate, and anhydrous dibasic calcium phosphate, can be used in addition or instead of the water soluble fillers.
  • the total weight percentage of filler ranges between about 5% and about 75% by weight.
  • a glidant can be used to improve powder flow properties prior to and during tabletting and to reduce caking.
  • Suitable glidants include colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, talc, tribasic calcium phosphate, and the like.
  • Colloidal silicon dioxide is preferably included as a glidant in an amount up to about 2%, preferably about 0.2% to about 0.8%, by weight of the tablet.
  • a lubricant can be used to enhance release of a tablet from apparatus on which it is formed, for example by preventing adherence to the face of an upper punch (“picking”) or lower punch (“sticking”).
  • Suitable lubricants include magnesium stearate, calcium stearate, canola oil, glyceryl palmitostearate, hydrogenated vegetable oil, magnesium oxide, mineral oil, poloxamer, polyethylene glycol, polyvinyl alcohol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc, hydrogenated vegetable oil, zinc stearate, and the like.
  • magnesium stearate is included as a lubricant in an amount of about 0.1% to about 1.5%, preferably about 0.3% to about 1%, by weight of the tablet.
  • agents such as polyvidone; copovidone; starch; acacia; gelatin; seaweed derivatives, e.g., alginic acid, sodium and calcium alginate; cellulose, preferably microcrystalline cellulose, cellulose derivatives, e.g., ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, having useful dry or wet binding and granulating properties; and antiadherents such as talc and magnesium stearate.
  • the matrix of the extended release tablet formulation of alternative a) comprises or essentially consists of pregelatinized starch, hydroxypropyl methyl cellulose and excipients.
  • the amount of pregelatinized starch is preferably in the range from 10 to 75%, particularly preferred from 25 to 65% most preferred from 45 to 55% by weight.
  • the amount of hydroxypropyl methyl cellulose is preferably in the range from 10 to 75%, particularly preferred from 25 to 65% most preferred from 35 to 55% by weight.
  • the amount of further excipients is preferably in the range from 0 to 30%, particularly preferred from 0.5 to 20%, most preferred from 1 to 10% by weight.
  • carboxymethyl cellulose sodium may additionally be present preferably in the range from 5 to 50, particularly preferred from 10 to 40, most preferred from 15 to 30% by weight.
  • formulation b) of the present invention it is provided a pH-dependent release profile, the release of pramipexole or its salt from the tablet and subsequent the absorption into the blood stream can vary during the passage of the dosage form along the gastrointestinal tract.
  • a pH-dependent release characteristic wherein the release characteristic in the range of pH ⁇ 4.5 is faster and a slower and further on pH-independent release characteristic in the range from 4.5 ⁇ pH ⁇ 7.5.
  • an anionic water swelling polymer preferably an acrylic acid polymerisate
  • formulation b which is preferably selected from carbomer or CARBOPOL® series, known acrylic acid polymerisates having high molecular weights. Particularly preferred are, for example, carbomer 941 (CARBOPOL® 71 G, CARBOPOL® 971) and carbomer 934 (CARBOPOL® 974).
  • the acrylic acid polymerisate is preferably present in the range of 0.25 to 25% by weight, particularly preferred 0.5 to 15% by weight, most preferred 1 to 10% by weight.
  • the pH dependency of formulation b) results form the presence of acrylic acid polymerisate which intends to swell in a greater extent in the acid pH range above pH 4.5 and in the alkaline pH range.
  • An increasing amount of acrylic acid leads to a decrease of the release rate. Therefore, adjusting the amount of acrylic acid polymerisate makes it possible to further tune the dissolution profiles as desired.
  • To adjust the amount of acrylic acid polymerisate in the preferred range from 0.25 to 25% by weight provides the further advantage that the desired, resp. matching, dissolution profiles can be adjusted, resp. maintained, for a variety of formulations composed of different amounts and/or types of gel-forming agents, water swelling polymers, fillers, and dry binders.
  • the matrix of the extended release tablet formulation of alternative b) comprises or essentially consists of pregelatinized starch, hydroxypropyl methyl cellulose acrylic acid polymerisate and excipients.
  • the amount of pregelatinized starch is preferably in the range from 10 to 75%, particularly preferred from 25 to 65% most preferred from 45 to 55% by weight.
  • the amount of hydroxypropyl methyl cellulose is preferably in the range from 10 to 75, particularly preferred from 25 to 65, most preferred from 35 to 55% by weight.
  • the amount of acrylic acid polymerisate is preferably as abovementioned.
  • the amount of excipients is preferably in the range from 0 to 30 particularly preferred from 0.5 to 20, most preferred from 1 to 10% by weight.
  • carboxymethyl cellulose sodium may additionally be present preferably in the range from 5 to 50, particularly preferred from 10 to 40, most preferred from 15 to 30% by weight.
  • pramipexole or a pharmaceutically acceptable salt thereof may be present in the formulation according to the present invention in any amount suitable for the desired treatment of a patient.
  • a preferred salt of pramipexole is the dihydrochloride salt, most preferably in the form of the monohydrate. Usual amounts are from about 0.1 to about 5 mg pramipexole salt. According to a particularly preferred embodiment, e.g., 0.750 mg pramipexole dihydrochloride monohydrate, corresponding to 0.524 mg anhydrous base, is used in the extended release tablet formulation according to the present invention.
  • any other amount of active ingredient suitable for treatment may be used with the only proviso that the amount of pramipexole or salt is sufficient to provide a daily dose in one to a small plurality, for example one to about 4, of tablets to be administered at one time.
  • the full daily dose is delivered in a single tablet.
  • An amount of pramipexole salt, expressed as pramipexole dihydrochloride monohydrate equivalent, of about 0.1 to about 10 mg per tablet, or about 0.05% to about 5% by weight of the composition will generally be suitable.
  • an amount of about 0.2 to about 6 mg, more preferably an amount of about 0.3 to about 5 mg, per tablet is present.
  • Specific dosage amounts per tablet e.g., include 0.375, 0.5, 0.75, 1.0, 1.5, 3.0, and 4.5 mg pramipexole dihydrochloride monohydrate.
  • the amount that constitutes a therapeutically effective amount varies according to the condition being treated, the severity of the condition, and the patient being treated.
  • An extended release tablet formulation according to the present invention has preferably the following composition:
  • a particularly preferred extended release tablet formulation of the present invention consists of:
  • a starch having a tensile strength of at least about 0.15 kN cm ⁇ 2 at a solid fraction representative of the tablet as claimed according to WO 2004/010997 is not necessary to practice the present invention.
  • the extended release tablet of the invention may comprise a nonfunctional coating.
  • a nonfunctional coating can comprise a polymer component, for example HPMC, optionally with other ingredients, for example one or more plasticizers, colorants, etc.
  • the term “nonfunctional” in the present context means having no substantial effect on release properties of the tablet, and the coating serves another useful purpose.
  • such a coating can impart a distinctive appearance to the tablet, provide protection against attrition during packaging and transportation, improve ease of swallowing, and/or have other benefits.
  • a nonfunctional coating should be applied in an amount sufficient to provide complete coverage of the tablet. Typically an amount of about 1% to about 10%, more typically an amount of about 2% to about 5%, by weight of the tablet as a whole, is suitable.
  • the tablets of the present invention can be of any suitable size and shape, for example round, oval, polygonal or pillow-shaped, and optionally bear nonfunctional surface markings. According to the present invention it is preferred that the extended release tablets are white to off-white and of oval or round, biconvex, shape.
  • Tablets of the invention can be packaged in a container, accompanied by a package insert providing pertinent information such as, for example, dosage and administration information, contraindications, precautions, drug interactions, and adverse reactions.
  • the present invention is further directed to the use of the extended release tablet formulation according to the present invention for preparing a medical composition for the treatment of Parkinson's Disease and complications or disorders associated therewith.
  • the present invention is preferably directed to a method of manufacturing the extended release tablet formulations via a diret compression process comprising the steps of:
  • the tablets are manufactured via a direct compression process which applies to both types of pramipexole extended release matrix tablets.
  • the active ingredient is preferably peg-milled.
  • the particle size distribution of the peg-milled drug substance is characterized by particle fraction of 90% (V/V) being smaller than 100 ⁇ m, most preferably a particle fraction of 90% (V/V) being smaller than 75 ⁇ m in diameter.
  • pramipexole extended release tablets like conventional wet granulation and roller compaction.
  • suitable fillers like, e.g., starch, microcrystalline cellulose, lactose monohydrate, or anhydrous dibasic calcium phosphate
  • wet binding agents like, e.g., hydroxypropyl methyl cellulose, hydroxypropylcellulose, povidone, copovidone, and starch paste, leading to a active ingredient concentrate, which after drying and dry screening is mixed with the main fraction of gel forming excipients, like all the above described retarding principles.
  • roller compaction or in other words dry granulation
  • a premix of pramipexole with part of the excipients used in the direct compression process, or the complete mixture containing all excipients is processed through a conventional roller compactor to form ribbons, which are thereafter screened down to granules which are further finally mixed with other excipients, like glidants, lubricants, and antiadherents.
  • FIG. 1 is a flow diagram illustrating a preferred embodiment of the direct compression manufacturing process according to the present invention
  • FIG. 2 is a graph illustrating the dissolution profiles of a matrix tablet formulation according to the present invention which contains 4% by weight CARBOPOL® in 3 different pH media;
  • FIG. 3 is a graph illustrating the dissolution profiles of 3 matrix tablet formulations according to the present invention which contain 0%, 1%, and 4% by weight of CARBOPOL®, respectively.
  • FIG. 1 illustrates a preferred embodiment of the manufacturing process with reference to a flow diagram wherein the manufacture of the extended release tablets of Examples 1 and 2 are exemplarily shown.
  • FIG. 1 shows the detailed process steps and the in process controls performed.
  • Process step (1) is directed to the active ingredient trituration, i.e., in the present case a salt of pramipexole, pramipexole dihydrochloride monohydrate, in peg-milled quality, is preblended with a portion of the water swelling polymer, in this case pregelatinized starch, in a commonly known mixer.
  • a TURBULA® free-fall mixer or blender is used. The mixing time is several minutes, in the present case preferably 10 minutes.
  • a premixing is performed, wherein the active ingredient trituration and the main portion of the water swelling polymer(s) and excipients are premixed for several minutes to obtain a pre-mix.
  • hydroxypropyl methyl cellulose hyperromellose
  • carbomer 941 and colloidal silicon dioxide are premixed for 5 minutes in the abovementioned TURBULA® mixer or blender.
  • a dry screening may optionally take place.
  • the pre-mixture may be manually screened through a screen, for example a 0.8 mm mesh size screen, in order to segregate cohesive particles and to improve content uniformity.
  • the main mixing step is performed according to which the components are mixed for several minutes, preferably 5 minutes in the TURBULA® mixer after screening.
  • further excipients may be added at this time, in the flow chart the component magnesium stearate is added to the main mixture, and further mixing for several minutes, e.g., 3 minutes, in the TURBULA® mixer is performed (final mixing) to obtain the final mixture.
  • Process step (5) of the process according to the present invention is the tabletting.
  • the final mixture is compressed on a suitable tablet press to produce, for example, oblong shaped matrix tablets (extended release tablets or ER tablets).
  • oblong shaped matrix tablets extended release tablets or ER tablets.
  • the obtained matrix tablets are subjected to the following in-process controls: tablet mass, hardness, tablet height, and friability.
  • the obtained pramipexole extended release tablets of the present invention may then be filled, for example, into High Density Polyethylene (HDPE) bottles.
  • HDPE High Density Polyethylene
  • the bottles are closed tightly with screw caps and appropriately labeled, whereby all packaging and labeling activities are performed according to cGMP regulations.
  • a blister type packaging can be used, e.g., using aluminum/aluminum foil blisters.
  • FIG. 2 represents a graph illustrating the dissolution profiles of a matrix tablet formulation according to the present invention.
  • the matrix tablet contains 4% by weight CARBOPOL®, the detailed composition is given in Example 2 and corresponds to the abovementioned formulation according to the present invention.
  • the value percent of released active ingredient is plotted against the time (hours).
  • FIG. 3 represents a graph illustrating the dissolution profiles of 3 matrix tablet formulations according to the present invention.
  • the matrix tablets contain no CARBOPOL®, 1% or 4% by weight CARBOPOL®, respectively, the detailed compositions are given in Examples 1, 2, and 4.
  • FIGS. 2 and 3 show a pH-independent in vitro release characteristic in the range from pH 1 to 7.5 in case CARBOPOL® is not present and a pH-dependent release characteristic wherein the release characteristic in the range of pH ⁇ 4.5 is faster in case CARBOPOL® is present.
  • An increase of the amount of CARBOPOL® leads to a decreased releasing rate.
  • extended release tablets containing pramipexole or its salt are available showing different in vitro release profiles. It is possible to select a tailor-made release characteristic for patient's needs, symptoms, and clinical picture observed.
  • the primary indication for pramipexole, Parkinson's Disease, is an affliction that becomes more prevalent with advancing age and is often accompanied by decline in memory. Therefore, the matrix tablets according to the present invention providing an extended or slow release of pramipexole or a salt thereof allows to simplify the patient's administration scheme by reducing the amount of recommended daily intakes and improves patient's compliance, particularly relevant for elderly patients.
  • the inventive extended release tablet formulation provides a daily dose preferably administered at one time.
  • the tablets of the present invention may be manufactured via a direct compression, wet or dry granulation process which applies to both types of extended release matrix tablets.
  • pramipexole extended release tablets have been manufactured.
  • the tablets of the Examples are white to off-white, 14 ⁇ 6.8 mm oblong shaped, biconvex tablets.
  • the tablets are intended to be administered orally, and shall not be divided into halves.
  • the pramipexole tablets in the Examples contain 0.75 mg of pramipexole dihydrochloride monohydrate, corresponding to 0.524 mg of pramipexole free, anhydrous base.
  • Example 3 The batch formula for the two pramipexole tablet formulations of Example 1 and 2 is shown in Table 3.
  • the batch size of the final mixture corresponds to a batch size of 2000 tablets.
  • TABLE 3 Composition per Batch of Pramipexole 0.75 mg ER Tablets Grams per Grams per batch batch Ingredient
  • Example 1 Example 2 Pramipexole dihydrochloride 1.500 1.500 monohydrate, peg-milled Hypromellose 2208 315.000 315.000 Pregelatinized starch 370.200 349.200 Carbomer 941 7.000 28.000 Colloidal silicon dioxide 2.800 2.800 Magnesium stearate 3.500 3.500 Total Mass 700.000 700.000 700.000 700.000
  • Example 4 shows a pramipexole tablet formulation which corresponds to formulation a) providing a release characteristic independent in the pH range of 1 to 7.5.
  • TABLE 4 Constituents mg/tablet Pramipexole dihydrochloride 0.750 monohydrate, peg-milled Hypromellose 2208 (Methocel K 100 M) 175.000 Pregelatinized starch 170.400 Colloidal silicon dioxide 2.100 Magnesium stearate 1.750 Total weight matrix tablet 350.000

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US11/202,715 2004-08-13 2005-08-12 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof Abandoned US20060051417A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/410,855 US20090182024A1 (en) 2004-08-13 2009-03-25 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04019248 2004-08-13
EP04019248.6 2004-08-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/410,855 Continuation US20090182024A1 (en) 2004-08-13 2009-03-25 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof

Publications (1)

Publication Number Publication Date
US20060051417A1 true US20060051417A1 (en) 2006-03-09

Family

ID=34926161

Family Applications (6)

Application Number Title Priority Date Filing Date
US11/202,715 Abandoned US20060051417A1 (en) 2004-08-13 2005-08-12 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US11/202,713 Active 2028-04-26 US7695734B2 (en) 2004-08-13 2005-08-12 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US12/410,855 Abandoned US20090182024A1 (en) 2004-08-13 2009-03-25 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US12/507,256 Active 2026-05-30 US8377977B2 (en) 2004-08-13 2009-07-22 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US13/647,865 Abandoned US20130274300A1 (en) 2004-08-13 2012-10-09 Extended Release Tablet Formulation Containing Pramipexole or a Pharmaceutically Acceptable Salt Thereof
US14/340,022 Abandoned US20140335175A1 (en) 2004-08-13 2014-07-24 Extended Release Tablet Formulation Containing Pramipexole or a Pharmaceutically Acceptable Salt Thereof

Family Applications After (5)

Application Number Title Priority Date Filing Date
US11/202,713 Active 2028-04-26 US7695734B2 (en) 2004-08-13 2005-08-12 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US12/410,855 Abandoned US20090182024A1 (en) 2004-08-13 2009-03-25 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US12/507,256 Active 2026-05-30 US8377977B2 (en) 2004-08-13 2009-07-22 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US13/647,865 Abandoned US20130274300A1 (en) 2004-08-13 2012-10-09 Extended Release Tablet Formulation Containing Pramipexole or a Pharmaceutically Acceptable Salt Thereof
US14/340,022 Abandoned US20140335175A1 (en) 2004-08-13 2014-07-24 Extended Release Tablet Formulation Containing Pramipexole or a Pharmaceutically Acceptable Salt Thereof

Country Status (32)

Country Link
US (6) US20060051417A1 (sr)
EP (6) EP1789021B2 (sr)
JP (5) JP4785847B2 (sr)
KR (2) KR101052436B1 (sr)
CN (4) CN101884626A (sr)
AR (1) AR050602A1 (sr)
AT (2) ATE532503T1 (sr)
AU (3) AU2005271192B2 (sr)
BR (2) BRPI0513846A (sr)
CA (3) CA2736965C (sr)
CY (2) CY1111713T1 (sr)
DE (1) DE602005024570D1 (sr)
DK (2) DK1789021T4 (sr)
EA (4) EA015335B1 (sr)
EC (2) ECSP077241A (sr)
ES (2) ES2355735T5 (sr)
HK (2) HK1104973A1 (sr)
HR (2) HRP20100682T4 (sr)
IL (3) IL181282A (sr)
ME (2) ME01316B (sr)
MX (2) MX2007001765A (sr)
NO (2) NO342453B1 (sr)
NZ (3) NZ553561A (sr)
PL (2) PL1789021T3 (sr)
PT (2) PT1781260E (sr)
RS (2) RS52057B2 (sr)
SG (1) SG148996A1 (sr)
SI (2) SI1789021T1 (sr)
TW (2) TWI347199B (sr)
UA (3) UA93608C2 (sr)
WO (2) WO2006015944A2 (sr)
ZA (2) ZA200700086B (sr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050175691A1 (en) * 2002-07-25 2005-08-11 Lee Ernest J. Pramipexole once-daily dosage form
US20060051419A1 (en) * 2004-08-13 2006-03-09 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US20060198887A1 (en) * 2004-08-13 2006-09-07 Boehringer Ingelheim International Gmbh Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US20080254117A1 (en) * 2007-04-10 2008-10-16 Noel Cotton Process for preparing pramipexole dihydrochloride tablets
US20090041844A1 (en) * 2006-02-10 2009-02-12 Boehringer Ingelheim International Gmbh Modified Release Formulation
US20090098202A1 (en) * 2006-02-10 2009-04-16 Boehringer Ingelheim International Gmbh Extended Release Formulation
US20090149451A1 (en) * 2004-08-25 2009-06-11 Essentialis, Inc. Pharmaceutical formulations of potassium atp channel openers and uses thereof
US20090186084A1 (en) * 2006-05-15 2009-07-23 Jean-Charles Schwartz Form of administration of racecadotril
US20100267960A1 (en) * 2006-08-24 2010-10-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing pramipexole dihydrochloride tablets
US8399016B2 (en) 2002-07-25 2013-03-19 Boehringer Ingelheim International Gmbh Sustained-release tablet composition of pramipexole
US9616027B2 (en) 2013-10-12 2017-04-11 Shijiazhuang Rapistep Pharmaceutical Technology R&D Inc. Pramipexole sustained release tablet formulation and manufacturing method thereof and use thereof
CN114869854A (zh) * 2022-04-18 2022-08-09 华裕(无锡)制药有限公司 一种生物等效性高的盐酸普拉克索缓释片及其制备方法

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
CN101299992A (zh) * 2005-11-04 2008-11-05 伊士曼化工公司 药物活性物质长效输送用羧烷基纤维素酯
WO2007090882A2 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Pharmaceutical extended release compositions comprising pramipexole
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
ATE537826T1 (de) * 2006-05-16 2012-01-15 Knopp Neurosciences Inc Zusammensetzungen aus r(+)- und s(-)-pramipexol sowie verfahren zu ihrer anwendung
WO2008009664A2 (en) * 2006-07-19 2008-01-24 Boehringer Ingelheim International Gmbh Treatment of pain
EP2056795A2 (en) * 2006-08-24 2009-05-13 Boehringer Ingelheim Pharma GmbH & Co. KG Process for preparing pramipexole dihydrochloride tablets with high storage stability
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US8519148B2 (en) 2007-03-14 2013-08-27 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
US20100092554A1 (en) * 2007-04-24 2010-04-15 Boehringer Ingelheim International Gmbh Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
EP2291178A4 (en) * 2008-06-09 2013-07-24 Supernus Pharmaceuticals Inc PRAMIPEXOL FORMULATIONS WITH CONTROLLED RELEASE
US20110190356A1 (en) 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
EP2448411A4 (en) * 2009-07-02 2012-11-28 Supernus Pharmaceuticals Inc METHOD OF TREATING A NEUROLOGICAL DISORDER
EP2525786A2 (en) 2010-01-18 2012-11-28 Synthon BV Pramipexole extended release tablets
US20120059013A1 (en) * 2010-03-09 2012-03-08 Boehringer Ingelheim International Gmbh Method of treating early morning akinesia in subjects having parkinson's disease
TR201001862A1 (tr) * 2010-03-11 2011-10-21 Sanovel �La� San.Ve T�C.A.�. Kontrollü salım gerçekleştiren pramipeksol formülasyonları.
KR101406265B1 (ko) * 2010-03-17 2014-06-12 영진약품공업주식회사 안정성이 개선된 프라미펙솔을 함유하는 약제학적 조성물 및 이의 제조방법
WO2011128914A2 (en) 2010-04-15 2011-10-20 Cadila Healthcare Limited Extended release pharmaceutical compositions of pramipexole
EP2380560A1 (de) * 2010-04-22 2011-10-26 ratiopharm GmbH Pramipexol enthaltende Matrixtablette
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
AU2011256928A1 (en) 2010-05-24 2012-12-20 Lupin Limited Extended release formulation of pramipexole
WO2013034173A1 (en) 2011-09-06 2013-03-14 Synthon Bv Pramipexole extended release tablets
KR101439635B1 (ko) * 2011-11-01 2014-09-11 대원제약주식회사 안정성이 향상된 엔테카비어를 함유하는 약학적 조성물 및 그 제조방법
CN102406626B (zh) * 2011-12-02 2013-08-28 深圳海王药业有限公司 盐酸普拉克索缓释片剂及其制备方法
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
IN2012DE00193A (sr) * 2012-01-23 2015-06-12 Ranbaxy Lab Ltd
CN102836137A (zh) * 2012-09-21 2012-12-26 山东齐都药业有限公司 一种高含量均匀度的盐酸普拉克索缓释片剂及其制备方法
EP2732812A1 (de) 2012-11-15 2014-05-21 Aristo Pharma GmbH Pramipexol-Retardtablettenformulierung
CN104744400B (zh) * 2012-11-22 2017-08-11 北京三泉医药技术有限公司 用于治疗神经疾病的四氢苯并噻唑衍生物
CN102988319B (zh) * 2012-12-10 2014-10-08 成都欣捷高新技术开发有限公司 一种ⅲ晶型盐酸普拉克索片剂及其制备方法
CN103040781B (zh) * 2013-01-04 2014-07-16 杭州朱养心药业有限公司 盐酸普拉克索片剂药物组合物及其制备方法
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
CN104161735A (zh) * 2013-05-19 2014-11-26 成都康弘药业集团股份有限公司 一种含有盐酸普拉克索的缓释制剂及其制备方法
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
PT3019167T (pt) 2013-07-12 2021-03-04 Knopp Biosciences Llc Tratamento de níveis elevados de eosinófilos e/ou basófilos
AU2014306597B2 (en) 2013-08-13 2018-05-17 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
US9642840B2 (en) 2013-08-13 2017-05-09 Knopp Biosciences, Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
CN105456216B (zh) * 2014-08-18 2019-11-05 江苏神龙药业股份有限公司 盐酸普拉克索缓释片剂组合物及其制备方法
JP2016113441A (ja) * 2014-10-27 2016-06-23 大原薬品工業株式会社 プラミペキソール二塩酸塩一水和物を含む放出が延長された錠剤
CN105796519A (zh) * 2014-12-30 2016-07-27 浙江京新药业股份有限公司 盐酸普拉克索缓释片及其制备方法
CN104606162B (zh) * 2015-01-07 2017-03-29 海南康虹医药科技开发有限公司 一种盐酸普拉克索缓释制剂及其制备方法
JP6366547B2 (ja) * 2015-08-03 2018-08-01 大原薬品工業株式会社 光安定性が向上した、プラミペキソール製剤包装体
CN105380917B (zh) * 2015-08-24 2019-01-15 江苏神华药业有限公司 一种盐酸普拉克索缓释片及其制备方法
CN106983729B (zh) * 2016-01-21 2021-02-26 北京北大维信生物科技有限公司 普拉克索缓释片及制备方法
CN107951853B (zh) * 2016-10-17 2022-04-08 海思科制药(眉山)有限公司 一种盐酸普拉克索缓释药物组合物及其制备方法
CN108785263B (zh) * 2017-04-26 2021-06-29 江苏恒瑞医药股份有限公司 普拉克索或其药用盐的固体药物组合物及其制备方法
DE18837223T1 (de) 2017-07-26 2020-03-26 Tgx Soft Chew, Llc Stärkefreier weicher kausnack für veterinärmedizinische anwendungen
US11234961B2 (en) 2017-08-17 2022-02-01 Zi-Qiang Gu Pamoate salt of monoamine anti-Parkinson's agents, method of preparation and use thereof
CN109966256B (zh) * 2017-12-28 2022-08-02 北京北大维信生物科技有限公司 一种普拉克索缓释药物组合物、其制备方法及用途
CN108159007B (zh) * 2017-12-29 2021-04-16 成都百裕制药股份有限公司 一种盐酸普拉克索缓释制剂及其制备方法
US20210228488A1 (en) * 2018-04-27 2021-07-29 Rubicon Research Private Limited Extended release compositions and process for preparation
CN112704668B (zh) * 2021-01-12 2022-09-30 石药集团中奇制药技术（石家庄）有限公司 一种盐酸普拉克索缓释组合物
CN112716908A (zh) * 2021-02-03 2021-04-30 上海雅本化学有限公司 一种普拉克索的制备工艺
CN113876729B (zh) * 2021-11-11 2023-05-30 南通联亚药业股份有限公司 一种盐酸普拉克索缓释片剂及其制备方法

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656027A (en) * 1981-06-18 1987-04-07 Astra Lakemedel Aktiebolag Pharmaceutical mixture
US4709712A (en) * 1986-10-22 1987-12-01 Dermatalogical Products Of Texas Polycarboxylic acid polymer gels as protective agents
US4738851A (en) * 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US4886812A (en) * 1984-12-22 1989-12-12 Dr. Karl Thomae Gmbh Tetrahydro-benzthiazoles, the preparation thereof and their use as intermediate products or as pharmaceuticals
US5078991A (en) * 1988-12-01 1992-01-07 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Topical composition
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5731338A (en) * 1992-07-02 1998-03-24 Oramed, Inc. Controlled release pilocarpine delivery system
US20020114831A1 (en) * 2000-12-15 2002-08-22 Inger Norden Pharmaceutical formulation
US20030133982A1 (en) * 2001-12-20 2003-07-17 Heimlich John M. Zero-order sustained release dosage forms and method of making same
US20040122104A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20050175691A1 (en) * 2002-07-25 2005-08-11 Lee Ernest J. Pramipexole once-daily dosage form
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US20060051419A1 (en) * 2004-08-13 2006-03-09 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US20060198887A1 (en) * 2004-08-13 2006-09-07 Boehringer Ingelheim International Gmbh Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2887440A (en) 1957-08-12 1959-05-19 Dow Chemical Co Enteric coating
US3065143A (en) 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
NL128902C (sr) * 1960-06-06
US3458622A (en) 1967-04-07 1969-07-29 Squibb & Sons Inc Controlled release tablet
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
JPS58403B2 (ja) 1975-07-24 1983-01-06 武田薬品工業株式会社 Ｌ− アスコルビンサンセイザイノ セイゾウホウ
US4167558A (en) 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4140755A (en) 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
CH649215A5 (de) 1981-04-29 1985-05-15 Hoffmann La Roche Pharmazeutische praeparate.
US4424235A (en) 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4666612A (en) * 1986-03-17 1987-05-19 Kerr-Mcgee Chemical Corporation Method for recovering a wood preservative from waste sludges
US4772473A (en) * 1986-06-16 1988-09-20 Norwich Eaton Pharmaceuticals, Inc. Nitrofurantoin dosage form
US4968508A (en) 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US4789549A (en) * 1987-03-09 1988-12-06 Warner-Lambert Company Sustained release dosage forms
US4859470A (en) 1988-06-02 1989-08-22 Alza Corporation Dosage form for delivering diltiazem
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
JP2955358B2 (ja) 1989-06-09 1999-10-04 ファルマシア・アンド・アップジョン・カンパニー 中枢神経系活性を有する複素環系アミン
US5273975A (en) 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
FR2653337B1 (fr) 1989-10-23 1992-02-07 Dow Corning Sa Element a liberation prolongee et procede pour le fabriquer.
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
JPH04234812A (ja) 1990-03-16 1992-08-24 Yamanouchi Pharmaceut Co Ltd 持続性製剤用顆粒
GB9015822D0 (en) * 1990-07-18 1990-09-05 Beecham Group Plc Compositions
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5656296A (en) 1992-04-29 1997-08-12 Warner-Lambert Company Dual control sustained release drug delivery systems and methods for preparing same
ATE219933T1 (de) 1992-09-18 2002-07-15 Yamanouchi Pharma Co Ltd Hydrogelzubereitung mit verzögerter freisetzung
DE4241013A1 (de) * 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung
US5458887A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
US5846971A (en) * 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
JPH1017497A (ja) * 1996-07-02 1998-01-20 Takeda Chem Ind Ltd 徐放性製剤およびその製造方法
GB9619074D0 (en) 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition
ES2248908T7 (es) 1997-06-06 2014-11-24 Depomed, Inc. Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
AU739261B2 (en) 1997-07-01 2001-10-11 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
AU8293498A (en) 1997-07-02 1999-01-25 Euro-Celtique S.A. Stabilized sustained release tramadol formulations
US5895663A (en) * 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
CA2211778A1 (en) 1997-08-14 1999-02-14 Francois Carriere Preparation of pregelatinized high amylose starch and debranched starch useful as an excipient for controlled release of active agents
US7153845B2 (en) 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US6624200B2 (en) 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
DE69819748T2 (de) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
DE69814428T2 (de) 1997-09-29 2004-05-13 Nektar Therapeutics, San Carlos In verneblern verwendbare, stabilisierte zubereitungen
US6197339B1 (en) 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US20020013304A1 (en) * 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US20020054911A1 (en) * 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
GB9802201D0 (en) 1998-02-03 1998-04-01 Cerestar Holding Bv Free-flowable directly compressible starch as binder,disintegrant and filler for compresion tablets and hard gelatine capsules
CA2323177A1 (en) 1998-03-11 1999-09-16 Susan Marie Milosovich Composition
EA200300125A1 (ru) 1998-05-15 2003-06-26 Фармация Энд Апджон Компани Применение каберголина для лечения полисистемной атрофии и прогрессирующего супрануклеарного паралича
GB9812426D0 (en) 1998-06-10 1998-08-05 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
US6312728B1 (en) 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation
TW407058B (en) 1998-07-17 2000-10-01 Dev Center Biotechnology Oral cisapride dosage forms with an extended duration
US20010055613A1 (en) 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
US6270805B1 (en) 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
DE19906290A1 (de) 1999-02-15 2000-08-17 Falk Pharma Gmbh Arzneimittel zur Behandlung bzw. Prävention von Darmkrebs
AR028986A1 (es) * 1999-02-23 2003-06-04 Smithkline Beecham Corp USO DE UN INHIBIDOR DE PDE4 EN LA FABRICACIoN DE UNA PREPARACIoN DE LIBERACIoN CONTROLADA; FORMULACION DE LIBERACION CONTROLADA PARA EL TRATAMIENTO DE COPD, UN PROCEDIMIENTO PARA SU PREPARACIoN Y COMPOSICIoN FARMACÉUTICA
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
BR0009437A (pt) 1999-03-31 2002-01-15 Janssen Pharmaceutica Nv Amido pré-gelatinizado em uma formulação de liberação controlada
DE19927688A1 (de) 1999-06-17 2000-12-21 Gruenenthal Gmbh Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
PT1459751E (pt) 1999-07-01 2005-11-30 Pharmacia & Upjohn Co Llc (s,s)-reboxetina para tratar as enxaquecas
ATE431141T1 (de) * 1999-07-13 2009-05-15 Alpha Res Group Llc Zusammensetzungen und verfahren zur behandlung der parkinson-krankheit
WO2001010405A1 (en) 1999-08-04 2001-02-15 Ranbaxy Laboratories Limited Hydrodynamically balanced oral drug delivery system
CO5210862A1 (es) 1999-09-15 2002-10-30 Alza Corp Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia
GB9923045D0 (en) 1999-09-29 1999-12-01 Novartis Ag New oral formulations
AU7620600A (en) 1999-09-30 2001-04-30 General Hospital Corporation, The Use of pramipexole as a treatment for cocaine craving
CN1409630A (zh) * 1999-10-19 2003-04-09 Nps药物有限公司 用于治疗cns－失调疾病之持续释放型制剂
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
KR20020082473A (ko) 1999-12-22 2002-10-31 파마시아 코포레이션 시클로옥시게나제-2 억제제의 지속-방출 조제물
US6467637B2 (en) 2000-01-27 2002-10-22 The York Group, Inc. Death care merchandising system
PE20011074A1 (es) * 2000-02-23 2001-10-04 Upjohn Co Uso de pramipexol en el tratamiento de trastornos de adiccion
CN1396829A (zh) 2000-02-24 2003-02-12 法玛西雅厄普约翰美国公司 新的药物联合形式
US6372252B1 (en) * 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US6277875B1 (en) * 2000-07-17 2001-08-21 Andrew J. Holman Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
EP1318813A4 (en) * 2000-08-08 2005-09-07 Teva Pharma STABLE PERGOLIDE MESYLATE AND PROCESS FOR MAKING SAME
ES2187249B1 (es) 2000-09-18 2004-09-16 Synthon Bv Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles.
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US20030022875A1 (en) * 2001-07-27 2003-01-30 Wilson Leland F. As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
US20030032661A1 (en) * 2001-08-02 2003-02-13 Boehringer Ingelheim Pharma Kg Pramipexole as an anticonvulsant
DE10138275A1 (de) 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
EP1480618B1 (en) * 2002-03-04 2009-06-03 Ipsen Pharma Sustained release drug formulations containing a carrier peptide
EP2425823A1 (en) 2002-04-05 2012-03-07 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
WO2003088952A1 (en) * 2002-04-15 2003-10-30 Adams Laboratories, Inc. Sustained release of guaifenesin combination drugs
US20030215498A1 (en) * 2002-05-17 2003-11-20 Harland Ronald S. Rapidly disintegrating comressed tablets comprising biologically active compounds
BR0311693A (pt) * 2002-06-10 2005-03-22 Wyeth Corp Sal de formato de o-desmetil-venlafaxina
MXPA05000018A (es) 2002-06-27 2005-04-08 Cilag Ag Formulaciones de pellas esfericas.
JP4478413B2 (ja) * 2002-07-11 2010-06-09 武田薬品工業株式会社 被覆製剤の製造法
FR2842734A1 (fr) * 2002-07-24 2004-01-30 Ethypharm Sa Procede pour diminuer la variabilite de la biodisponibilite d'un medicament a administration orale et compositions pharmaceutiques a administration orale
AR040680A1 (es) * 2002-07-25 2005-04-13 Pharmacia Corp Composicion de tabletas de liberacion sostenida
US20040137156A1 (en) * 2002-07-25 2004-07-15 Lee Ernest J Coated solid dosage form and method for preparing same
AU2003224467A1 (en) * 2003-03-11 2004-09-30 Korea United Pharm, Inc. Process for the preparing of hardcapsule formulation containing lansoprazole
MXPA05010636A (es) 2003-04-04 2005-12-12 Pharmacia Corp Comprimidos de multiparticulas preparados por compresion de liberacion oral prolongada.
US20050020589A1 (en) 2003-06-18 2005-01-27 Pfizer Inc. Sustained-release tablet composition comprising a dopamine receptor agonist
WO2006046256A1 (en) 2004-10-27 2006-05-04 Alembic Limited Extended release formulation of pramipexole dihydrochloride
WO2007002518A1 (en) 2005-06-23 2007-01-04 Spherics, Inc. Delayed release or extended-delayed release dosage forms of pramipexole
US20070003621A1 (en) 2005-06-23 2007-01-04 Spherics, Inc. Dosage forms for movement disorder treatment
ES2334061T3 (es) 2005-08-15 2010-03-04 University Of Virginia Patent Foundation Neurorrestauracion con pramipexol r(+).
WO2007054976A2 (en) 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition
WO2007090882A2 (en) 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Pharmaceutical extended release compositions comprising pramipexole
WO2007090883A1 (en) 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
WO2007090881A2 (en) 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Modified release formulation
EP1886665A1 (en) 2006-08-01 2008-02-13 Boehringer Ingelheim Pharma GmbH & Co. KG Gastro retentive delivery system
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
EA200900270A1 (ru) * 2006-08-25 2009-08-28 Бёрингер Ингельхайм Интернациональ Гмбх Системы регулируемого высвобождения и способ их приготовления

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656027A (en) * 1981-06-18 1987-04-07 Astra Lakemedel Aktiebolag Pharmaceutical mixture
US4886812A (en) * 1984-12-22 1989-12-12 Dr. Karl Thomae Gmbh Tetrahydro-benzthiazoles, the preparation thereof and their use as intermediate products or as pharmaceuticals
US4738851A (en) * 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US4709712A (en) * 1986-10-22 1987-12-01 Dermatalogical Products Of Texas Polycarboxylic acid polymer gels as protective agents
US5078991A (en) * 1988-12-01 1992-01-07 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Topical composition
US5731338A (en) * 1992-07-02 1998-03-24 Oramed, Inc. Controlled release pilocarpine delivery system
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US20020114831A1 (en) * 2000-12-15 2002-08-22 Inger Norden Pharmaceutical formulation
US20030133982A1 (en) * 2001-12-20 2003-07-17 Heimlich John M. Zero-order sustained release dosage forms and method of making same
US20050175691A1 (en) * 2002-07-25 2005-08-11 Lee Ernest J. Pramipexole once-daily dosage form
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US20040122104A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20060051419A1 (en) * 2004-08-13 2006-03-09 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US20060198887A1 (en) * 2004-08-13 2006-09-07 Boehringer Ingelheim International Gmbh Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399016B2 (en) 2002-07-25 2013-03-19 Boehringer Ingelheim International Gmbh Sustained-release tablet composition of pramipexole
US20050175691A1 (en) * 2002-07-25 2005-08-11 Lee Ernest J. Pramipexole once-daily dosage form
US7695734B2 (en) 2004-08-13 2010-04-13 Boehringer Ingelheim International Gmbh Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US20060051419A1 (en) * 2004-08-13 2006-03-09 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US20060198887A1 (en) * 2004-08-13 2006-09-07 Boehringer Ingelheim International Gmbh Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US8715728B2 (en) 2004-08-13 2014-05-06 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US20090182024A1 (en) * 2004-08-13 2009-07-16 Boehringer Ingelheim International Gmbh Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US8377977B2 (en) 2004-08-13 2013-02-19 Boehringer Ingelheim International Gmbh Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US20090281153A1 (en) * 2004-08-13 2009-11-12 Boehringer Ingelheim International Gmbh Extended Release Tablet Formulation Containing Pramipexole or a Pharmaceutically Acceptable Salt Thereof
US20100086589A1 (en) * 2004-08-13 2010-04-08 Thomas Friedl Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US20090149451A1 (en) * 2004-08-25 2009-06-11 Essentialis, Inc. Pharmaceutical formulations of potassium atp channel openers and uses thereof
US20090098202A1 (en) * 2006-02-10 2009-04-16 Boehringer Ingelheim International Gmbh Extended Release Formulation
US20110195122A1 (en) * 2006-02-10 2011-08-11 Boehringer Ingelheim International Gmbh Extended Release Formulation
US20090041844A1 (en) * 2006-02-10 2009-02-12 Boehringer Ingelheim International Gmbh Modified Release Formulation
US8318203B2 (en) * 2006-05-15 2012-11-27 Bioprojet Form of administration of racecadotril
US20090186084A1 (en) * 2006-05-15 2009-07-23 Jean-Charles Schwartz Form of administration of racecadotril
US20100267960A1 (en) * 2006-08-24 2010-10-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing pramipexole dihydrochloride tablets
US20100252949A1 (en) * 2007-04-10 2010-10-07 Boehringer Ingelheim International Gmbh Process for Preparing Pramipexole Dihydrochloride Tablets
US20080254117A1 (en) * 2007-04-10 2008-10-16 Noel Cotton Process for preparing pramipexole dihydrochloride tablets
US9616027B2 (en) 2013-10-12 2017-04-11 Shijiazhuang Rapistep Pharmaceutical Technology R&D Inc. Pramipexole sustained release tablet formulation and manufacturing method thereof and use thereof
CN114869854A (zh) * 2022-04-18 2022-08-09 华裕(无锡)制药有限公司 一种生物等效性高的盐酸普拉克索缓释片及其制备方法

Also Published As

Publication number Publication date
UA86831C2 (uk) 2009-05-25
EA200700132A1 (ru) 2007-08-31
WO2006015944A3 (en) 2007-02-08
IL220313A0 (en) 2012-07-31
US20090281153A1 (en) 2009-11-12
TW200618821A (en) 2006-06-16
EA200900930A1 (ru) 2009-12-30
PT1789021E (pt) 2011-12-22
EA200700201A1 (ru) 2007-08-31
CA2736965C (en) 2014-02-18
BRPI0513846A (pt) 2008-05-20
EP1781260B1 (en) 2010-11-03
ATE486588T1 (de) 2010-11-15
TW201100126A (en) 2011-01-01
AU2005271192A1 (en) 2006-02-16
CN101005830B (zh) 2010-09-29
US20090182024A1 (en) 2009-07-16
US20130274300A1 (en) 2013-10-17
TWI347850B (en) 2011-09-01
JP2011126916A (ja) 2011-06-30
EP2368545A1 (en) 2011-09-28
AU2011250676A1 (en) 2011-12-01
EP1781260B9 (en) 2011-02-16
UA93608C2 (ru) 2011-02-25
JP4757872B2 (ja) 2011-08-24
PL1789021T3 (pl) 2012-04-30
NZ553561A (en) 2010-12-24
DK1789021T4 (da) 2014-11-10
HRP20120068T1 (en) 2012-02-29
EP1789021B1 (en) 2011-11-09
DK1781260T4 (da) 2014-06-23
BRPI0513847A (pt) 2008-05-20
CN101005830A (zh) 2007-07-25
EP2286801A2 (en) 2011-02-23
RS51527B (sr) 2011-06-30
SI1789021T1 (sl) 2012-02-29
TWI347199B (en) 2011-08-21
ATE532503T1 (de) 2011-11-15
ECSP077241A (es) 2007-03-29
HRP20120068T4 (hr) 2015-02-13
CN101005831B (zh) 2010-11-10
RS52057B2 (sr) 2018-03-30
EA201001083A1 (ru) 2011-08-30
EP2286801A3 (en) 2012-05-09
CA2572729A1 (en) 2006-02-16
ES2355735T3 (es) 2011-03-30
JP2009102409A (ja) 2009-05-14
PT1781260E (pt) 2010-12-20
JP2008509192A (ja) 2008-03-27
IL181283A0 (en) 2007-07-04
ME01316B (me) 2013-12-20
RS51527B2 (sr) 2018-02-28
KR20070052300A (ko) 2007-05-21
CN101884626A (zh) 2010-11-17
EP2135602A1 (en) 2009-12-23
CA2572864A1 (en) 2006-02-16
EP1781260A1 (en) 2007-05-09
IL181283A (en) 2013-12-31
EP1789021A2 (en) 2007-05-30
CY1111713T1 (el) 2015-10-07
ECSP077242A (es) 2007-05-30
EP1781260B2 (en) 2014-04-02
DK1781260T3 (da) 2011-02-21
AU2005271192B2 (en) 2011-11-17
US20140335175A1 (en) 2014-11-13
WO2006015942A1 (en) 2006-02-16
EP1789021B2 (en) 2014-10-08
CY1112268T1 (el) 2015-12-09
CA2572729C (en) 2011-06-21
KR101406767B1 (ko) 2014-06-20
AR050602A1 (es) 2006-11-08
SI1781260T2 (sl) 2014-08-29
CA2736965A1 (en) 2006-02-16
EA016850B1 (ru) 2012-08-30
SG148996A1 (en) 2009-01-29
SI1781260T1 (sl) 2011-02-28
CA2572864C (en) 2014-02-11
DK1789021T3 (da) 2012-03-05
PL1781260T3 (pl) 2011-04-29
NO20070733L (no) 2007-03-06
US8377977B2 (en) 2013-02-19
WO2006015944A2 (en) 2006-02-16
KR101052436B1 (ko) 2011-07-29
HK1104973A1 (en) 2008-02-01
HK1104974A1 (en) 2008-02-01
UA89052C2 (ru) 2009-12-25
NO342453B1 (no) 2018-05-22
DE602005024570D1 (de) 2010-12-16
US7695734B2 (en) 2010-04-13
MX2007001765A (es) 2007-04-20
AU2005271194A1 (en) 2006-02-16
KR20070046172A (ko) 2007-05-02
EP2345407A1 (en) 2011-07-20
NZ553587A (en) 2010-12-24
AU2005271194B2 (en) 2011-11-24
NO20070719L (no) 2007-03-02
RS52057B (sr) 2012-04-30
US20060198887A1 (en) 2006-09-07
ES2377214T3 (es) 2012-03-23
ZA200700086B (en) 2008-02-27
NZ589267A (en) 2012-06-29
IL181282A0 (en) 2007-07-04
CN101849921A (zh) 2010-10-06
HRP20100682T1 (en) 2011-01-31
IL181282A (en) 2012-10-31
JP2008509194A (ja) 2008-03-27
PL1781260T5 (pl) 2014-09-30
ES2355735T5 (es) 2014-06-27
ME01442B (me) 2013-12-20
MX2007001706A (es) 2007-04-12
CN101005831A (zh) 2007-07-25
JP4785847B2 (ja) 2011-10-05
EA015335B1 (ru) 2011-06-30
ZA200700085B (en) 2008-02-27
JP2011084577A (ja) 2011-04-28
HRP20100682T4 (hr) 2014-08-01

Similar Documents

Publication Publication Date Title
US7695734B2 (en) Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
AU2011244983A1 (en) Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FRIEDL, THOMAS;EISENREICH, WOLFRAM;REEL/FRAME:017026/0118

Effective date: 20051024

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION